Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in Int J Oncol

Retrieve available abstracts of 76 articles:
HTML format

Single Articles

    August 2021
  1. WEN C, Liu X, Ma H, Zhang W, et al
    [Retracted] miR3383p suppresses tumor growth of ovarian epithelial carcinoma by targeting Runx2.
    Int J Oncol. 2021;59.
    PubMed     Abstract available

    July 2021
  2. CHAUVIN M, Garambois V, Choblet S, Colombo PE, et al
    Anti-Mullerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival.
    Int J Oncol. 2021;59.
    PubMed     Abstract available

    May 2021
  3. THONGCHOT S, Jamjuntra P, Therasakvichya S, Warnnissorn M, et al
    Interleukin8 released by cancerassociated fibroblasts attenuates the autophagy and promotes the migration of ovarian cancer cells.
    Int J Oncol. 2021;58.
    PubMed     Abstract available

    April 2021
  4. WANG J, Wu Y, Li Y, Wang Y, et al
    Guanosine monophosphate synthase upregulation mediates cervical cancer progression by inhibiting the apoptosis of cervical cancer cells via the Stat3/P53 pathway.
    Int J Oncol. 2021;58:1.
    PubMed     Abstract available

    December 2020
  5. DEVOR EJ, Gonzalez-Bosquet J, Thiel KW, Leslie KK, et al
    Genomic characterization of five commonly used endometrial cancer cell lines.
    Int J Oncol. 2020;57:1348-1357.
    PubMed     Abstract available

  6. LI L, Yu J, Duan Z, Dang HX, et al
    [Corrigendum] The effect of NFATc1 on vascular generation and the possible underlying mechanism in epithelial ovarian carcinoma.
    Int J Oncol. 2020;57:1381.
    PubMed     Abstract available

    September 2020
  7. LIU J, Liu D, Liu JJ, Zhao C, et al
    [Corrigendum] Blocking the Nav1.5 channel using eicosapentaenoic acid reduces migration and proliferation of ovarian cancer cells.
    Int J Oncol. 2020 Sep 28. doi: 10.3892/ijo.2020.5129.
    PubMed     Abstract available

  8. YANOKURA M, Banno K, Aoki D
    MicroRNA34b expression enhances chemosensitivity of endometrial cancer cells to paclitaxel.
    Int J Oncol. 2020 Sep 23. doi: 10.3892/ijo.2020.5127.
    PubMed     Abstract available

  9. LIU L, Yuan L, Huang D, Han Q, et al
    miR126 regulates the progression of epithelial ovarian cancer in vitro and in vivo by targeting VEGFA.
    Int J Oncol. 2020;57:825-834.
    PubMed     Abstract available

    August 2020
  10. XU J, Lu W
    FAM83A exerts tumorsuppressive roles in cervical cancer by regulating integrins.
    Int J Oncol. 2020;57:509-521.
    PubMed     Abstract available

    July 2020
  11. ROSENDO-CHALMA P, Antonio-Vejar V, Bigoni-Ordonez GD, Patino-Morales CC, et al
    CDH1 and SNAI1 are regulated by E7 from human papillomavirus types 16 and 18.
    Int J Oncol. 2020;57:301-313.
    PubMed     Abstract available

    June 2020
  12. WANG F, Li J, Wang H, Zhang F, et al
    Activating transcription factor 3 inhibits endometrial carcinoma aggressiveness via JunB suppression.
    Int J Oncol. 2020 Jun 19. doi: 10.3892/ijo.2020.5084.
    PubMed     Abstract available

    May 2020
  13. WANG X, De Geyter C, Jia Z, Peng Y, et al
    HECTD1 regulates the expression of SNAIL: Implications for epithelialmesenchymal transition.
    Int J Oncol. 2020;56:1186-1198.
    PubMed     Abstract available

    April 2020
  14. GUO F, Zhang K, Li M, Cui L, et al
    miR5083p suppresses the development of ovarian carcinoma by targeting CCNA2 and MMP7.
    Int J Oncol. 2020 Apr 27. doi: 10.3892/ijo.2020.5055.
    PubMed     Abstract available

  15. XIN W, Zhao S, Han X, Zhao P, et al
    lncRNA LA16c313D11.11 modulates the development of endometrial cancer by binding to and inhibiting microRNA2055p function and indirectly increasing PTEN activity.
    Int J Oncol. 2020 Apr 13. doi: 10.3892/ijo.2020.5046.
    PubMed     Abstract available

  16. LIAO S, Liang L, Yue C, He J, et al
    CD38 is involved in cell energy metabolism via activating the PI3K/AKT/mTOR signaling pathway in cervical cancer cells.
    Int J Oncol. 2020 Apr 8. doi: 10.3892/ijo.2020.5040.
    PubMed     Abstract available

  17. HUANG J, Diao G, Zhang Q, Chen Y, et al
    E6regulated overproduction of prostaglandin E2 may inhibit migration of dendritic cells in human papillomavirus 16positive cervical lesions.
    Int J Oncol. 2020;56:921-931.
    PubMed     Abstract available

    March 2020
  18. WANG L, Tan Z, Zhang Y, Kady Keita N, et al
    ADAM12 silencing promotes cellular apoptosis by activating autophagy in choriocarcinoma cells.
    Int J Oncol. 2020 Mar 5. doi: 10.3892/ijo.2020.5007.
    PubMed     Abstract available

  19. ZHANG L, Zhang B, Wei M, Xu Z, et al
    TRIM22 inhibits endometrial cancer progression through the NOD2/NFkappaB signaling pathway and confers a favorable prognosis.
    Int J Oncol. 2020 Mar 4. doi: 10.3892/ijo.2020.5004.
    PubMed     Abstract available

    February 2020
  20. XUE Y, Sun R, Zheng W, Yang L, et al
    Forskolin promotes vasculogenic mimicry and invasion via Notch1activated epithelialtomesenchymal transition in syncytiolization of trophoblast cells in choriocarcinoma.
    Int J Oncol. 2020 Feb 20. doi: 10.3892/ijo.2020.4997.
    PubMed     Abstract available

    January 2020
  21. BU H, Li Y, Jin C, Yu H, et al
    Overexpression of PRC1 indicates a poor prognosis in ovarian cancer.
    Int J Oncol. 2020 Jan 10. doi: 10.3892/ijo.2020.4959.
    PubMed     Abstract available

  22. FENG Y, Tang Y, Mao Y, Liu Y, et al
    PAX2 promotes epithelial ovarian cancer progression involving fatty acid metabolic reprogramming.
    Int J Oncol. 2020 Jan 10. doi: 10.3892/ijo.2020.4958.
    PubMed     Abstract available

    December 2019
  23. LEE SY, Kwon J, Woo JH, Kim KH, et al
    Bcl2l10 mediates the proliferation, invasion and migration of ovarian cancer cells.
    Int J Oncol. 2019 Dec 23. doi: 10.3892/ijo.2019.4949.
    PubMed     Abstract available

    November 2019
  24. LIU Q, Liu H, Li L, Dong X, et al
    ATAD2 predicts poor outcomes in patients with ovarian cancer and is a marker of proliferation.
    Int J Oncol. 2019 Nov 14. doi: 10.3892/ijo.2019.4913.
    PubMed     Abstract available

  25. RIERA LEAL A, Ortiz-Lazareno PC, Jave-Suarez LF, Ramirez De Arellano A, et al
    17betaestradiolinduced mitochondrial dysfunction and Warburg effect in cervical cancer cells allow cell survival under metabolic stress.
    Int J Oncol. 2019 Nov 14. doi: 10.3892/ijo.2019.4912.
    PubMed     Abstract available

  26. BAI Y, Li LD, Li J, Chen RF, et al
    A FXYD5/TGFbeta/SMAD positive feedback loop drives epithelialtomesenchymal transition and promotes tumor growth and metastasis in ovarian cancer.
    Int J Oncol. 2019 Nov 13. doi: 10.3892/ijo.2019.4911.
    PubMed     Abstract available

    September 2019
  27. YE W, Ni Z, Yicheng S, Pan H, et al
    Anisomycin inhibits angiogenesis in ovarian cancer by attenuating the molecular sponge effect of the lncRNAMeg3/miR421/PDGFRA axis.
    Int J Oncol. 2019 Sep 30. doi: 10.3892/ijo.2019.4887.
    PubMed     Abstract available

  28. LI R, Wang Y, Xu Y, He X, et al
    Silencing the long noncoding RNA, TINCR, a molecular sponge of miR335, inhibits the malignant phenotype of epithelial ovarian cancer via FGF2 suppression.
    Int J Oncol. 2019 Sep 10. doi: 10.3892/ijo.2019.4875.
    PubMed     Abstract available

    July 2019
  29. SEKIYA A, Suzuki S, Tanaka A, Hattori S, et al
    Interleukin33 expression in ovarian cancer and its possible suppression of peritoneal carcinomatosis.
    Int J Oncol. 2019 Jul 17. doi: 10.3892/ijo.2019.4845.
    PubMed     Abstract available

    June 2019
  30. JIANG S, Chang H, Deng S, Fan D, et al
    Icariin enhances the chemosensitivity of cisplatinresistant ovarian cancer cells by suppressing autophagy via activation of the AKT/mTOR/ATG5 pathway.
    Int J Oncol. 2019;54:1933-1942.
    PubMed     Abstract available

    May 2019
  31. WANG L, Chen T, Li X, Yan W, et al
    USP39 promotes ovarian cancer malignant phenotypes and carboplatin chemoresistance.
    Int J Oncol. 2019 May 29. doi: 10.3892/ijo.2019.4818.
    PubMed     Abstract available

  32. GUAN W, Wang X, Lin Q, Zhang J, et al
    Transforming growth factorbeta/miR1433p/cystatin B axis is a therapeutic target in human ovarian cancer.
    Int J Oncol. 2019 May 28. doi: 10.3892/ijo.2019.4815.
    PubMed     Abstract available

  33. KIM BI, Kim JH, Sim DY, Nam M, et al
    Inhibition of JAK2/STAT3 and activation of caspase9/3 are involved in KYS05090Sinduced apoptosis in ovarian cancer cells.
    Int J Oncol. 2019 May 3. doi: 10.3892/ijo.2019.4795.
    PubMed     Abstract available

  34. BU S, Li B, Wang Q, Gu T, et al
    Epithelial ovarian cancer stemlike cells are resistant to the cellular lysis of cytokineinduced killer cells via HIF1Amediated downregulation of ICAM1.
    Int J Oncol. 2019 May 3. doi: 10.3892/ijo.2019.4794.
    PubMed     Abstract available

  35. ZHA H, Li X, Sun H, Duan L, et al
    S100A9 promotes the proliferation and migration of cervical cancer cells by inducing epithelialmesenchymal transition and activating the Wnt/betacatenin pathway.
    Int J Oncol. 2019 May 2. doi: 10.3892/ijo.2019.4793.
    PubMed     Abstract available

  36. ZHOU Y, Wang W, Wei R, Jiang G, et al
    Serum bradykinin levels as a diagnostic marker in cervical cancer with a potential mechanism to promote VEGF expression via BDKRB2.
    Int J Oncol. 2019 May 2. doi: 10.3892/ijo.2019.4792.
    PubMed     Abstract available

    March 2019
  37. HERNANDEZ-JUAREZ J, Vargas-Sierra O, Herrera LA, Cantu De Leon D, et al
    Sodium-coupled monocarboxylate transporter is a target of epigenetic repression in cervical cancer.
    Int J Oncol. 2019 Mar 14. doi: 10.3892/ijo.2019.4749.
    PubMed     Abstract available

  38. ZHANG W, Ou X, Wu X
    Proteomics profiling of plasma exosomes in epithelial ovarian cancer: A potential role in the coagulation cascade, diagnosis and prognosis.
    Int J Oncol. 2019 Mar 7. doi: 10.3892/ijo.2019.4742.
    PubMed     Abstract available

    February 2019
  39. LEE J, An S, Jung JH, Kim K, et al
    MUL1 E3 ligase regulates the antitumor effects of metformin in chemoresistant ovarian cancer cells via AKT degradation.
    Int J Oncol. 2019 Feb 27. doi: 10.3892/ijo.2019.4730.
    PubMed     Abstract available

  40. CHEN YN, Ren CC, Yang L, Nai MM, et al
    MicroRNA let7d5p rescues ovarian cancer cell apoptosis and restores chemosensitivity by regulating the p53 signaling pathway via HMGA1.
    Int J Oncol. 2019 Feb 27. doi: 10.3892/ijo.2019.4731.
    PubMed     Abstract available

    January 2019
  41. LIU L, Yang L, Chang H, Chen YN, et al
    CP31398 attenuates endometrial cancer cell invasion, metastasis and resistance to apoptosis by downregulating MDM2 expression.
    Int J Oncol. 2019 Jan 9. doi: 10.3892/ijo.2019.4681.
    PubMed     Abstract available

    December 2018
  42. TAE IH, Park EY, Dey P, Son JY, et al
    Novel SIRT1 inhibitor 15-deoxy-Delta12,14-prostaglandin J2 and its derivatives exhibit anticancer activity through apoptotic or autophagic cell death pathways in SKOV3 cells.
    Int J Oncol. 2018;53:2518-2530.
    PubMed     Abstract available

    November 2018
  43. LI S, Zhao X, Chang S, Li Y, et al
    ERp57small interfering RNA silencing can enhance the sensitivity of drugresistant human ovarian cancer cells to paclitaxel.
    Int J Oncol. 2018 Nov 7. doi: 10.3892/ijo.2018.4628.
    PubMed     Abstract available

  44. CHEN J, Jia Y, Jia ZH, Zhu Y, et al
    Silencing the expression of MTDH increases the radiation sensitivity of SKOV3 ovarian cancer cells and reduces their proliferation and metastasis.
    Int J Oncol. 2018;53:2180-2190.
    PubMed     Abstract available

  45. LIU S, Wang F, Liu G
    Knockdown of pleiotrophin increases the risk of preeclampsia following vitrified-thawed embryo transfer.
    Int J Oncol. 2018;53:1847-1856.
    PubMed     Abstract available

  46. LIU J, Zhen YZ, Cui J, Hu G, et al
    Dynamic influence of Rhein lysinate on HeLa cells.
    Int J Oncol. 2018;53:2047-2055.
    PubMed     Abstract available

    September 2018
  47. NING L, Long B, Zhang W, Yu M, et al
    Circular RNA profiling reveals circEXOC6B and circN4BP2L2 as novel prognostic biomarkers in epithelial ovarian cancer.
    Int J Oncol. 2018 Sep 20. doi: 10.3892/ijo.2018.4566.
    PubMed     Abstract available

    August 2018
  48. PAPPA KI, Christou P, Xholi A, Mermelekas G, et al
    Membrane proteomics of cervical cancer cell lines reveal insights on the process of cervical carcinogenesis.
    Int J Oncol. 2018 Aug 7. doi: 10.3892/ijo.2018.4518.
    PubMed     Abstract available

    July 2018
  49. SKIRNISDOTTIR I, Akerud H, Seidal T
    Clinical significance of growth factor receptor EGFR and angiogenesis regulator VEGFR2 in patients with ovarian cancer at FIGO stages I-II.
    Int J Oncol. 2018 Jul 31. doi: 10.3892/ijo.2018.4511.
    PubMed     Abstract available

  50. YOSHIDA M, Taguchi A, Kawana K, Ogishima J, et al
    Intraperitoneal neutrophils activated by KRAS-induced ovarian cancer exert antitumor effects by modulating adaptive immunity.
    Int J Oncol. 2018 Jul 26. doi: 10.3892/ijo.2018.4504.
    PubMed     Abstract available

  51. LV Q, Wu K, Liu F, Wu W, et al
    Interleukin17A and heparanase promote angiogenesis and cell proliferation and invasion in cervical cancer.
    Int J Oncol. 2018 Jul 26. doi: 10.3892/ijo.2018.4503.
    PubMed     Abstract available

  52. LIU J, Zheng M, Qi Y, Wang H, et al
    Lewis(y) antigen-mediated positive feedback loop induces and promotes chemotherapeutic resistance in ovarian cancer.
    Int J Oncol. 2018 Jul 20. doi: 10.3892/ijo.2018.4496.
    PubMed     Abstract available

  53. XU Y, Gao W, Zhang Y, Wu S, et al
    ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
    Int J Oncol. 2018 Jul 9. doi: 10.3892/ijo.2018.4476.
    PubMed     Abstract available

    June 2018
  54. LIU J, Liu D, Liu JJ, Zhao C, et al
    Blocking the Nav1.5 channel using eicosapentaenoic acid reduces migration and proliferation of ovarian cancer cells.
    Int J Oncol. 2018 Jun 12. doi: 10.3892/ijo.2018.4437.
    PubMed     Abstract available

  55. MUNGUIA-MORENO JA, Diaz-Chavez J, Garcia-Villa E, Albino-Sanchez ME, et al
    Early synergistic interactions between the HPV16E7 oncoprotein and 17beta-oestradiol for repressing the expression of Granzyme B in a cervical cancer model.
    Int J Oncol. 2018 Jun 6. doi: 10.3892/ijo.2018.4432.
    PubMed     Abstract available

    May 2018
  56. KANG MA, Kim W, Jo HR, Shin YJ, et al
    Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS032, on cervical cancer.
    Int J Oncol. 2018 May 31. doi: 10.3892/ijo.2018.4424.
    PubMed     Abstract available

  57. SONG J, Zhang W, Wang S, Liu K, et al
    A panel of 7 prognosis-related long non-coding RNAs to improve platinum-based chemoresistance prediction in ovarian cancer.
    Int J Oncol. 2018 May 11. doi: 10.3892/ijo.2018.4403.
    PubMed     Abstract available

  58. SHEN L, Sun B, Sheng J, Yu S, et al
    PGC1alpha promotes cisplatin resistance in human ovarian carcinoma cells through upregulation of mitochondrial biogenesis.
    Int J Oncol. 2018 May 9. doi: 10.3892/ijo.2018.4401.
    PubMed     Abstract available

    April 2018
  59. QIU C, Wang Y, Wang X, Zhang Q, et al
    Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
    Int J Oncol. 2018 Apr 4. doi: 10.3892/ijo.2018.4360.
    PubMed     Abstract available

  60. WANG Y, Qiu C, Lu N, Liu Z, et al
    FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner.
    Int J Oncol. 2018 Apr 4. doi: 10.3892/ijo.2018.4359.
    PubMed     Abstract available

    March 2018
  61. TANG G, Guo J, Zhu Y, Huang Z, et al
    Metformin inhibits ovarian cancer via decreasing H3K27 trimethylation.
    Int J Oncol. 2018 Mar 29. doi: 10.3892/ijo.2018.4343.
    PubMed     Abstract available

  62. KIM SY, Kwon SK, Lee SY, Baek KH, et al
    Ubiquitin-specific peptidase 5 and ovarian tumor deubiquitinase 6A are differentially expressed in p53+/+ and p53-/- HCT116 cells.
    Int J Oncol. 2018 Mar 5. doi: 10.3892/ijo.2018.4302.
    PubMed     Abstract available

    February 2018
  63. TIAN R, Li X, Gao Y, Li Y, et al
    Identification and validation of the role of matrix metalloproteinase-1 in cervical cancer.
    Int J Oncol. 2018 Feb 7. doi: 10.3892/ijo.2018.4267.
    PubMed     Abstract available

  64. YUAN Y, Ye HQ, Ren QC
    Upregulation of the BDNF/TrKB pathway promotes epithelial-mesenchymal transition, as well as the migration and invasion of cervical cancer.
    Int J Oncol. 2018;52:461-472.
    PubMed     Abstract available

    January 2018
  65. XU M, Xiao J, Chen M, Yuan L, et al
    miR1495p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway.
    Int J Oncol. 2018 Jan 24. doi: 10.3892/ijo.2018.4252.
    PubMed     Abstract available

  66. SATO N, Saga Y, Uchibori R, Tsukahara T, et al
    Eradication of cervical cancer in vivo by an AAV vector that encodes shRNA targeting human papillomavirus type 16 E6/E7.
    Int J Oncol. 2018 Jan 15. doi: 10.3892/ijo.2018.4245.
    PubMed     Abstract available

  67. WANG Y, Yu X, Song H, Feng D, et al
    The STAT-ROS cycle extends IFNinduced cancer cell apoptosis.
    Int J Oncol. 2018;52:305-313.
    PubMed     Abstract available

    November 2017
  68. CHANG RK, Li X, Mu N, Hrydziuszko O, et al
    MicroRNA expression profiles in nonepithelial ovarian tumors.
    Int J Oncol. 2017 Nov 10. doi: 10.3892/ijo.2017.4200.
    PubMed     Abstract available

    October 2017
  69. PENG F, Zhong Y, Liu Y, Zhang Y, et al
    SPARC suppresses lymph node metastasis by regulating the expression of VEGFs in ovarian carcinoma.
    Int J Oncol. 2017 Oct 19. doi: 10.3892/ijo.2017.4168.
    PubMed     Abstract available

  70. OZRETIC P, Trnski D, Musani V, Maurac I, et al
    Non-canonical Hedgehog signaling activation in ovarian borderline tumors and ovarian carcinomas.
    Int J Oncol. 2017 Oct 12. doi: 10.3892/ijo.2017.4156.
    PubMed     Abstract available

  71. SHETA R, Bachvarova M, Plante M, Gregoire J, et al
    Altered expression of different GalNActransferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer.
    Int J Oncol. 2017 Oct 9. doi: 10.3892/ijo.2017.4147.
    PubMed     Abstract available

  72. PAN H, Wang F, Rankin GO, Rojanasakul Y, et al
    Inhibitory effect of black tea pigments, theaflavin3/3'-gallate against cisplatin-resistant ovarian cancer cells by inducing apoptosis and G1 cell cycle arrest.
    Int J Oncol. 2017 Oct 3. doi: 10.3892/ijo.2017.4145.
    PubMed     Abstract available

  73. GUO J, Cai J, Zhang Y, Zhu Y, et al
    Establishment of two ovarian cancer orthotopic xenograft mouse models for in vivo imaging: A comparative study.
    Int J Oncol. 2017;51:1199-1208.
    PubMed     Abstract available

  74. LAI Y, Fan L, Zhao Y, Ge H, et al
    Cx32 suppresses extrinsic apoptosis in human cervical cancer cells via the NFkappaB signalling pathway.
    Int J Oncol. 2017;51:1159-1168.
    PubMed     Abstract available

    September 2017
  75. LIAO S, Xiao S, Chen H, Zhang M, et al
    The receptor for activated protein kinase C promotes cell growth, invasion and migration in cervical cancer.
    Int J Oncol. 2017 Sep 27. doi: 10.3892/ijo.2017.4137.
    PubMed     Abstract available

  76. BU S, Zhang Q, Wang Q, Lai D, et al
    Human amniotic epithelial cells inhibit growth of epithelial ovarian cancer cells via TGFbeta1-mediated cell cycle arrest.
    Int J Oncol. 2017 Sep 14. doi: 10.3892/ijo.2017.4123.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.